Equity Profile

AUPH

AURINIA PHARMACEUTIC Equity

Health CareBiotechnology$2.0B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health.

$0.25

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases. With a market cap of $2 billion, its innovations could significantly impact patient care in the health care sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

In Q1 2026, Aurinia reported an EPS of $0.25, exceeding expectations by 38.89%. However, the stock fell 6.80% the following day, indicating mixed market reactions despite the positive earnings surprise.

Management Promises & Guidance

Focus on expanding its product pipeline.
Commitment to enhancing research and development efforts.
Plans to improve operational efficiencies.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Aurinia's upcoming earnings, especially after a strong performance in the last quarter. However, uncertainty remains due to the lack of revenue guidance.

Bull Case

If Aurinia can deliver strong EPS and demonstrate solid revenue growth, it could validate investor confidence and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.25

EPS is a crucial indicator of the company's profitability and financial health.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market presence and drive sales.

Market Reaction

N/A

Understanding how the stock reacts post-earnings can provide insights into investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026?

The EPS figure will be critical for assessing the company's profitability and could influence investor sentiment.

What guidance will management provide for revenue growth?

Clear revenue guidance is essential for understanding the company's future prospects and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Aurinia's potential for revenue growth, as recent product developments could drive stronger sales than anticipated.

Supporting Evidence

The company's recent EPS surprises indicate a trend of exceeding expectations.

Options pricing suggests higher volatility, indicating that investors are preparing for significant news.

The stock's historical performance shows resilience after earnings surprises.

Key Risk

If the EPS comes in below $0.20, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Aurinia can sustain its recent earnings momentum and provide credible growth forecasts.

Bull Confirmed If

An EPS of $0.25 or higher with positive revenue commentary would confirm the bull case.

Bear Confirmed If

An EPS below $0.20 or negative revenue guidance would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations, history suggests a potential stock increase of around 1.03%, confirming positive market sentiment.

In-Line / Cautious

If the results are in line with expectations, the stock may see limited movement as investors await further clarity from management.

Miss

A miss on EPS could lead to a decline of approximately 1.44%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming launches.
2Details on operational efficiencies and cost management strategies.
3Management's outlook on market conditions and competitive landscape.
4Insights into customer adoption rates for new therapies.
5Any commentary on partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health.

$0.25

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

Management Promises & Guidance

Focus on expanding its product pipeline.
Commitment to enhancing research and development efforts.
Plans to improve operational efficiencies.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Aurinia's upcoming earnings, especially after a strong performance in the last quarter. However, uncertainty remains due to the lack of revenue guidance.

Bull Case

If Aurinia can deliver strong EPS and demonstrate solid revenue growth, it could validate investor confidence and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.25

EPS is a crucial indicator of the company's profitability and financial health.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market presence and drive sales.

Market Reaction

N/A

Understanding how the stock reacts post-earnings can provide insights into investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026?

The EPS figure will be critical for assessing the company's profitability and could influence investor sentiment.

What guidance will management provide for revenue growth?

Clear revenue guidance is essential for understanding the company's future prospects and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Aurinia's potential for revenue growth, as recent product developments could drive stronger sales than anticipated.

Supporting Evidence

The company's recent EPS surprises indicate a trend of exceeding expectations.

Options pricing suggests higher volatility, indicating that investors are preparing for significant news.

The stock's historical performance shows resilience after earnings surprises.

Key Risk

If the EPS comes in below $0.20, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Aurinia can sustain its recent earnings momentum and provide credible growth forecasts.

Bull Confirmed If

An EPS of $0.25 or higher with positive revenue commentary would confirm the bull case.

Bear Confirmed If

An EPS below $0.20 or negative revenue guidance would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations, history suggests a potential stock increase of around 1.03%, confirming positive market sentiment.

In-Line / Cautious

If the results are in line with expectations, the stock may see limited movement as investors await further clarity from management.

Miss

A miss on EPS could lead to a decline of approximately 1.44%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming launches.
2Details on operational efficiencies and cost management strategies.
3Management's outlook on market conditions and competitive landscape.
4Insights into customer adoption rates for new therapies.
5Any commentary on partnerships or collaborations that could enhance growth.